Platelet inhibition by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance?

The majority of patients who suffer peri-operative thromboembolic complication while undergoing vascular procedures do so despite taking aspirin. This study examined the antiplatelet effect of aspirin during surgery in patients undergoing carotid endarterectomy (CEA). Fifty patients undergoing CEA were standardised to 150 mg aspirin daily for > or =2 weeks. Platelet aggregation in response to arachidonic acid (AA) was measured in platelet rich plasma prepared from blood taken prior to, during, and at the end of surgery. Spontaneous platelet aggregation was also studied, as was the role of physiological agonists (ADP, collagen, thrombin, and epinephrine) in mediating the in vivo and in vitro responses to AA. Eighteen patients undergoing leg angioplasty, also on 150 mg aspirin, without general anaesthesia, served as a control group. In the CEA patients aggregation induced by AA (5 mM) increased significantly from 7.6 +/- 5.5% pre-surgery to 50.8 +/- 29.5% at the end of surgery (p <0.0001). Aggregation to AA was even greater in samples taken mid-surgery from a sub-set of patients (73.8+/-7.2%; p = 0.0001), but fell to 45.9 +/- 7.4% by the end of surgery. The increased aggregation in response to AA was not due to intra-operative release of physiological platelet agonists since addition of agents that block/neutralise the effects of ADP (apyrase; 4 micro g/ml), thrombin (hirudin; 10 units/ml), or epinephrine (yohimbine; 10 micro M/l) to the samples taken at the end of surgery did not block the increased aggregation. The patients undergoing angioplasty also showed a significant rise in the response to AA (5 mM), from 5.6 +/- 5.5% pre-angioplasty to 32.4 +/- 24.9% at the end of the procedure (p <0.0001), which fell significantly to 11.0 +/- 8.1% 4 hours later. The antiplatelet activity of aspirin, mediated by blockade of platelet arachidonic acid metabolism, diminished significantly during surgery, but was partially restored by the end of the procedure without additional aspirin treatment. This rapidly inducible and transient effect may explain why some patients undergoing cardiovascular surgery remain at risk of peri-operative stroke and myocardial infarction.

[1]  Chris I. Jones,et al.  Beneficial Effects of Clopidogrel Combined With Aspirin in Reducing Cerebral Emboli in Patients Undergoing Carotid Endarterectomy , 2004, Circulation.

[2]  K. Schrör,et al.  Functional and Biochemical Evaluation of Platelet Aspirin Resistance After Coronary Artery Bypass Surgery , 2003, Circulation.

[3]  C. Patrono,et al.  Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Z. Ungvari,et al.  Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[5]  S. Yusuf,et al.  Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events , 2002, Circulation.

[6]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[7]  A. Nicolaides,et al.  Platelet Activation During Carotid Endarterectomy And the Antiplatelet effect of Dextran 40 , 2002, Platelets.

[8]  K. Schrör,et al.  Towards a definition of aspirin resistance: a typological approach , 2002, Platelets.

[9]  E. Topol,et al.  Profile and prevalence of aspirin resistance in patients with cardiovascular disease. , 2001, The American journal of cardiology.

[10]  H. Sinzinger,et al.  Do human platelets express COX-2? , 2001, Prostaglandins, leukotrienes, and essential fatty acids.

[11]  P. Shankaranarayanan,et al.  Evidence for the presence of phospholipid hydroperoxide glutathione peroxidase in human platelets: implications for its involvement in the regulatory network of the 12-lipoxygenase pathway of arachidonic acid metabolism. , 2001, The Biochemical journal.

[12]  R Brian Haynes,et al.  Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial , 1999, The Lancet.

[13]  J. Meyer-Kirchrath,et al.  Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance , 1999, The Lancet.

[14]  V. Fuster,et al.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[15]  A. Buchan.  North American Symptomatic Carotid Endarterectomy Trial (NASCET) Steering Committee. The Benefit of Carotid Endarterectomy in Symptomatic Patients with Moderate and Severe Stenosis. , 1998 .

[16]  C J Knight,et al.  Increased platelet responsiveness following coronary stenting. Heparin as a possible aetiological factor in stent thrombosis. , 1998, European heart journal.

[17]  P. Cannistraro,et al.  Collagen-induced whole blood platelet aggregation in patients undergoing surgical procedures associated with minimal to moderate blood loss. , 1998, American journal of clinical pathology.

[18]  C. Funk,et al.  Increased platelet sensitivity to ADP in mice lacking platelet-type 12-lipoxygenase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  V. Fuster,et al.  The Relationships Among Dose, Effectiveness, and Side Effects , 1998 .

[20]  M. Lagarde,et al.  Low concentrations of lipid hydroperoxides prime human platelet aggregation specifically via cyclo-oxygenase activation. , 1997, The Biochemical journal.

[21]  J. Maclouf,et al.  Cyclooxygenases-1 and −2 of Endothelial Cells Utilize Exogenous or Endogenous Arachidonic Acid for Transcellular Production of Thromboxane (*) , 1996, The Journal of Biological Chemistry.

[22]  S. Brister,et al.  Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. , 1995, The Canadian journal of cardiology.

[23]  L. Brace,et al.  Development of Aspirin Resistance in Persons With Previous Ischemic Stroke , 1994, Stroke.

[24]  C. Wale,et al.  Thrombin generation in patients undergoing carotid endarterectomy: implications in acute vessel wall closure and antithrombotic therapy. , 1994, Thrombosis research.

[25]  B. Bull,et al.  Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. , 1994, Archives of pathology & laboratory medicine.

[26]  P. T. Larsson,et al.  Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. , 1994, Circulation.

[27]  Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy , 1994, BMJ.

[28]  P. Hjemdahl,et al.  Epinephrine sensitizes human platelets in vivo and in vitro as studied by fibrinogen binding and P-selectin expression. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[29]  T. Olivecrona,et al.  New aspects on heparin and lipoprotein metabolism. , 1993, Haemostasis.

[30]  G. Sicard.  MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70–99%) or mild (0–29%) carotid stenosis: European Carotid Surgery Trialist' Collaborative Group. Lancet 1991;337:1235-43 , 1992 .

[31]  G. Bengtsson-Olivecrona,et al.  Hydrolysis of chylomicron polyenoic fatty acid esters with lipoprotein lipase and hepatic lipase. , 1991, Biochimica et biophysica acta.

[32]  C. Warlow,et al.  MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis , 1991, The Lancet.

[33]  T. Jensen,et al.  MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group , 1991 .

[34]  B. Chong,et al.  The mechanism of heparin‐induced platelet aggregation , 1989, European journal of haematology.

[35]  M. Horne,et al.  Heparin binding to resting and activated platelets. , 1989, Blood.

[36]  J. Cazenave,et al.  Epinephrine potentiates human platelet activation but is not an aggregating agent. , 1988, The American journal of physiology.

[37]  P. Sørensen,et al.  Danish very-low-dose aspirin after carotid endarterectomy trial. , 1988, Stroke.

[38]  I. Morita,et al.  Role of 12-lipoxygenase products of arachidonic acid on platelet aggregation. , 1987, Advances in prostaglandin, thromboxane, and leukotriene research.

[39]  J. Hirsh,et al.  Role of lipoxygenase metabolism in platelet function: effect of aspirin and salicylate. , 1986, Prostaglandins, leukotrienes, and medicine.

[40]  G. FitzGerald,et al.  Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. , 1983, The Journal of clinical investigation.

[41]  C. Patrono,et al.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. , 1982, The Journal of clinical investigation.

[42]  G J Roth,et al.  Acetylation of prostaglandin synthase by aspirin. , 1975, Proceedings of the National Academy of Sciences of the United States of America.